Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Different doses of glycopyrrolate vs atropine for prevention of neostigmine-induced bradycardia
ChiCTR2200058489Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of glycopyrronium in bradyarrhythmia (3 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Area under the curve of difference between heart rate and baseline heart rate within 15 minutes after experimental drug administration and Heart rate variability. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
glycopyrronium
03
Conditions
bradyarrhythmia
Beyond the preview
Go deeper on ChiCTR2200058489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058489.